Sheng-Guang Li – InmunoES

Complement-amplified thrombotic microangiopathy in systemic lupus erythematosus and lupus nephritis: a systematic review of 78 reported patients

30 de September de 2026 by Sheng-Guang Li

BackgroundThrombotic microangiopathy (TMA) complicating systemic lupus erythematosus (SLE) and lupus nephritis (LN) spans immune thrombotic thrombocytopenic purpura, anti-phospholipid-associated microangiopathy, secondary endothelial injury, and comple…

CAR-based cellular therapy for refractory systemic lupus erythematosus: an overlap-controlled systematic review

1 de July de 2026 by Sheng-Guang Li

ObjectivesTo define the current evidence for CAR-based cellular therapy in relapsed or refractory systemic lupus erythematosus (SLE) by resolving overlapping reports and synthesising patient-level phenotype, safety and efficacy data. The primary purpos…

Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides

4 de June de 2026 by Sheng-Guang Li

Immune-mediated inflammatory arthritides (IMIA), including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and juvenile idiopathic arthritis, are chronic immune-driven disorders in which long-term malignancy safety has become a key …